STANFORD UNIVERSITY

The Transdermal Drug Delivery Pipeline Report, 2024 Update, offers comprehensive insights into pipeline products, development stages, clinical trials, and key companies shaping the transdermal drug delivery market.

Dr. Parag Mallick, a Stanford professor and Nautilus Biotechnology co-founder, envisions a future where proteomics addresses global challenges. His Nautilus platform aims to measure the entire proteome in a single experiment, using innovative techniques like Protein Identification by Short Epitope Mapping (PrISM) and nanofabricated landing pads. Mallick's diverse passions, including circus performance and magic, enrich his scientific approach, emphasizing the importance of individuality in science.

A study in twins reveals genetic makeup determines flu vaccine protection, challenging 'original antigenic sin' theory. Researchers designed a vaccine using a molecular matrix scaffold to induce immune response to multiple flu subtypes, enhancing protection against diverse strains.

Baby's first vocalizations linked to heart rate, indicating speech development tied to autonomic nervous system, per University of Houston study.

The NIH All of Us Research Program faces funding challenges, necessitating reconsideration of priorities and seeking additional funding sources. Despite budget cuts, the program has achieved significant milestones, including new genetic discoveries and improved precision medicine. A working group suggests exploring ancillary studies, researcher fees, and management efficiencies for sustainability.

University of Arizona's research activity exceeded $1 billion in FY24, focusing on global challenges like energy, health, and national security. The university ranks among top research institutions and maintains its No. 1 ranking in astronomy and astrophysics. Research advances human knowledge, prepares students, and strengthens communities.

Researchers from CHOP and Stanford developed TRACeR-I, a molecular platform for reprogramming immune responses to target cancer cells via high affinity binders to peptide-MHC complexes. Published in Nature Biotechnology, it offers broad compatibility and simpler development for MHC-targeting molecules.

Nutcracker Therapeutics faces challenges in manufacturing RNA-based drugs for personalized therapies and bridging small-scale companies to clinical trial-scale studies. Scaling up mRNA and LNP manufacturing for small startups remains costly and inefficient.

RBS2418, an oral immunotherapy drug developed by Riboscience, targets advanced colorectal cancer, offering new hope for terminal patients in Vietnam. The drug, approved by the FDA and Vietnam’s Ministry of Health, activates the immune system to recognize and destroy cancer cells. The VISTA-1 trial, involving 150 patients in the U.S. and Vietnam, marks Vietnam’s first Phase 2A clinical trial for colorectal cancer treatment, enhancing the country’s role in global medical research.

Researchers from CHOP and Stanford revealed TRACeR-I's molecular structure, a protein platform for reprogramming immune responses, which could optimize cancer treatment designs. TRACeRs act as 'master keys' for MHC proteins, overcoming historical hurdles in MHC-targeting molecules, with high specificity and broad compatibility.